Lixte in the News and Media:

New anticancer compounds
could boost effectiveness of standard therapies

Lixte is developing new drug candidates that could safely bolster the effectiveness of chemotherapy and radiation and treat several diseases.
November 2013: "Biopharma Dealmakers",
Nature Biotechnology, pg. 14-15
Click here to download PDF
Investor Information
Lixte Biotechnology Holdings, Inc. is publicly traded as LIXT.

Lixte Biotechnology Holdings Inc. SEC & XBRL Filings


Investor Contact:
Lixte Biotechnology Holdings, Inc.
248 Route 25A No. 2
East Setauket, NY 11733
((212) 634-6474 (T)
(928) 982 5050 (F)